血浆S100B蛋白预测动脉瘤性蛛网膜下腔出血短期预后及并发症的研究  

Plasma S100B as a predictor for short-term outcome of aneurysmal subarachnoid hemorrhage(aSAH)and in hospital complications

作　　者：杨波[1] 刘艳芳[1] 边立衡[1] 赵性泉[1] 

机构地区：[1]首都医科大学附属北京天坛医院神经病学中心,北京100050

出　　处：《中国神经精神疾病杂志》2015年第11期674-678,共5页Chinese Journal of Nervous and Mental Diseases

摘　　要：目的测定动脉瘤性蛛网膜下腔出血（aneurysmal subarachnoid hemorrhage,a SAH）患者急性期血浆中S100B蛋白水平,评价其对该病短期临床预后及并发症的预测价值。方法连续入组天坛医院1年内发病72h内a SAH患者以及正常健康对照。采集患者临床信息,留取患者及对照组血样标本,通过ELISA法测定其血浆中S100B蛋白水平,分析其对a SAH患者短期预后不良和院内并发症的预测价值。结果纳入符合标准的患者118例,健康对照组130例,与对照组相比a SAH急性期血浆S100B水平升高（28.55 pg/m L vs.21.20 pg/m L,P〈0.001）。入院时Hunt-Hess分级3~5级（P〈0.001）、住院期间发生迟发型脑缺血（P〈0.001）、血浆S100B蛋白水平增高（P=0.05）以及脑积水（P=0.028）的患者预后不良风险明显增高。血浆S100B蛋白水平高的患者院内并发症风险增加（P=0.049）。结论急性期血浆S100B蛋白增高可预测a SAH短期功能预后不良以及院内并发症的发生。Objective To study the ability of S100B to predict the clinical outcomes and complications after aneu- rysmal subarachnoid hemorrhage （aSAH）. Method This study is a one-center and consecutive recruitment. Plasma S100B levels were measured by enzyme-linked immune-sorbent assay （ELISA） within 72 hours after onset. The charac- teristics, treatment patterns, complications and outcomes of patients were also analyzed. Results The S100B levels of aSAH patients were higher than that of health controls（28.55 pg/mL vs. 21.20 pg/mL, P〈0.001）. S100B levels （P=0.05）, Hunt-Hess higher scales （P〈0.001）, delayed cerebral ischemia （P〈0.001） and hydrocephalus （P=0.028） were associated with poor outcomes. S100B also can predict complications in hospital. Conclusions The levels of S100B rise during acute phase of aSAH and S100B may be a useful biomarker to predict functional outcomes and complications in hospital.

关 键 词：S100B蛋白 动脉瘤性蛛网膜下腔出血 预后 并发症 

分 类 号：R743.35[医药卫生—神经病学与精神病学]